A first-in-human phase 1 study of KB 9558 in multiple myeloma
Latest Information Update: 04 Sep 2024
At a glance
- Drugs KB 9558 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 04 Sep 2024 According to a Kronos Bio media release, the company will present oral presentation at the International Myeloma Society (IMS) 21st Annual Meeting, taking place September 25 - 28, 2024 in Rio de Janeiro, Brazil.
- 21 Mar 2024 According to a Kronos Bio media release, IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence and expect to dose first patients in the first half of 2025.
- 12 Mar 2024 New trial record